BioScrip, Inc. (BIOS) reported third-quarter earnings of 14 cents per share, beating the Zacks Consensus Estimate of 10 cents. The company reported earnings of 6 cents in the year-ago period. Although earnings were better than expected, revenues declined 7.2% to $333.5 million. While the specialty business contributed $279 million to revenues, the pharmacy benefit management (PBM) business posted revenues of $54.5 million.   The decline in revenues was mainly due to the elimination of the Medicare Competitive Acquisition Program and the termination of the United Health Group organ transplant and HIV/AIDS contracts. This was partially offset by increased sales of higher margin infusion therapies and other specialty sales.   The company reported a sequential growth of 3% in specialty sales with several therapeutic areas like iron overload, multiple sclerosis (MS), oncology and infusion therapies recording double digit growth from the year-ago period. The oral oncology business should continue ...

One company that has been gaining acclaim in their industry, but not on Wall Street, is NanoViricides. An odd series of events is causing confusion in the marketplace.

NanoViricides is a development stage company that is creating special purpose nanomaterials for viral therapy. Based in Connecticut, the young company has gained raved reviews for its HIVCode which could result in a functional cure for HIV/AIDS. Besides the HIVCode, NanoViricides has been making progress in all aspects of their company.

NanoViricides has reported that it is well-financed into the future and its game changing anti-viral and drug programs have continued to develop successfully. Recently, Nano announced that is raised $4.3 million in equity financing which should be sufficient for 18 months or beyond December 2010.

Leading the way at Nano is Dr. Eugene Seymour who serves as their CEO. Dr. Seymour is a renowned name in the industry

...

Recently, Allion Healthcare Inc. (ALLI) inked a deal with an affiliate of H.I.G. Capital, LLC, a leading global private investment firm, whereby it agreed to be acquired by the private company. The deal is worth approximately $278 million. The amount is inclusive of the assumption or repayment of about $79 million of indebtedness. The transaction is expected to close in the first quarter of 2010.  Under the terms of the transaction, Allion shareholders would receive $6.60 per share in cash. This represents a premium of 30.2% over Allion's five-day average closing price before the announcement of the deal. Consequently, this transaction provides substantial financial gains to Allion shareholders. The transaction has been approved by Allion’s Board of Directors.  Additionally, other shareholders of Allion, including Parallex LLC, who in aggregate hold approximately 41.1 % of the company’s outstanding shares have agreed to vote in favor of the ...

Dr Stock Pick HOT News & Alerts!

_________________________________________

FREE Daily Stock Alerts From DrStockPick.com

_________________________________________

DrStockPick.com Watch List!

My Picks for Friday October 16, 2009, are:

**************************************************************

HSC, Harsco Corp.

HSC is a diversified industrial services company serving global industries that are fundamental to worldwide economic growth, including infrastructure, metals, railways and energy.

HSC is recognized as one of the Fortune 1000 leading companies in America and has been named five times to the Platinum 400 list of the best big companies by Forbes magazine.

HSC signed a new, multi-million dollar supply contract which expands its business with a major asphalt shingle manufacturer in the United States.

**************************************************************

ACAS, American Capital, Ltd.

ACAS, both directly and through its global asset management business,

...

Dr Stock Pick HOT News & Alerts!

_______________________________________

FREE Daily Stock Alerts From DrStockPick.com

_______________________________________

Thursday October 15, 2009

DrStockPick.com Stock Report!

**************************************************************

Power3 Medical Products, Inc. (OTCBB: PWRM), a leader in neurodegenerative disease and cancer biomarkers and diagnostic tests, announces further international recognition of validity as the company’s President and CSO, Dr. Ira Goldknopf, will deliver an invited Keynote address and chair a session on “Biomarkers and Diagnostics in Personalized Medicine (Track 6-4),” at the BIT Life Sciences 2nd International Congress and Expo of Molecular Diagnostics in Beijing, China, November 19-21, 2009. The Theme of the meeting is “New Leadership of

...

GeoVax Labs, Inc., an Atlanta-based, biopharmaceutical company developing human vaccines for HIV/AIDS (HIV-1, Human Immunodeficiency Virus), today told the investment community of partial success in the recently completed Phase 3 trial in Thailand of a candidate HIV/AIDS vaccine. According to the press release, this completed study represents the first HIV/AIDS vaccine trial to show prevention of infection.

Robert McNally, Ph.D., Chief Executive Officer and President stated, “The results are highly encouraging for the clinical studies of our HIV/AIDS vaccine and we congratulate the Thai ministry of Public Health for successful conduct of a groundbreaking trial that included 16,000 volunteers and was supported by multiple agencies including the U.S. Army and the U.S. National Institutes of Health (NIH).”

“The partial success of this trial is very important to the GeoVax vaccine, because the vaccine tested in Thailand, like the GeoVax vaccine, was designed to elicit both T cells and antibody,” commented Dr. Harriet

...

Dr Stock Pick HOT News & Alerts!

_______________________________________

FREE Daily Stock Alerts From DrStockPick.com

_______________________________________

Thursday September 24, 2009

DrStockPick.com Stock Report!

**************************************************************

DISH Network Corporation (Nasdaq: DISH) today announced that its subsidiary, DISH DBS Corporation, plans to offer approximately $300 million aggregate principal amount of debt securities. The net proceeds of the offering are intended to be used for general corporate purposes.

Seaway Valley Capital Corporation (OTC Bulletin Board: SWVL), a diversified holding company with its subsidiary, Hackett’s Stores, Inc. (Pink Sheets: HCKE), today announced that newly hired Vice President Herbert Becker will be promoted to President of Patrick

...

DrStockPick.com Stock Report!

Tuesday September 8, 2009

**************************************************************

Heathrow Natural Food & Beverage, Inc. (PINKSHEETS: HRNF) is pleased to provide an update for shareholders on several fronts. The initial sample shipment of ACAI Plus has arrived and is waiting clearance at U.S. Customs in Port Elizabeth, NJ. The gum will be tested at an independent consumer laboratory for content and antioxidant levels and made available to multiple distributors who will bring it to the retail market. Heathrow Natural Food & Beverage, Inc. has ordered an initial production run of 250,000 units and expects to ship over four million units of ACAI Plus over the next

...

ImmuneRegen BioSciences, Inc., a wholly owned subsidiary of IR BioSciences Holdings, Inc., announced this morning that it has executed a Material Transfer Agreement (MTA) with Archimedes Development Limited. This collaboration enables the companies to identify possible synergies between their technology platforms.

“Multiple studies in different model systems have shown that Homspera can protect experimental animals and enhance their immune responses to vaccine-delivered antigens, DNA-encoded viral proteins or tumor antigens, as well as provide protection in our anthrax and influenza therapeutic studies,” stated Hal Siegel, Ph.D., ImmuneRegen’s Vice President and Chief Scientific Officer.

He continued, “In addition to these findings in animals where Homspera has been administered intranasally as a liquid, inhaled or injected under the skin, we have shown in laboratory studies that Homspera can stimulate blood-forming stem cells to produce more white blood cell precursors, particularly those for granulocytes and macrophages, mature blood cells which play a significant role in

...

Yesterday, Mylan Inc. (MYL) announced that its Indian subsidiary, Matrix Laboratories, received tentative approval from the US Food and Drug Administration (FDA) under the President's Emergency Plan for AIDS Relief (PEPFAR) for its generic version of a fixed-dose combination of Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate tablets in 600 mg/200mg/300 mg dosage strengths.

The decision is in response to an Abbreviated New Drug Application filed by the Indian subsidiary. The tentative approval under PEPFAR is indicative of the fact that the product satisfies all the manufacturing quality, safety and efficacy standards laid down by the agency.

The Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate combination is the generic version of Gilead Sciences’ (GILD) Atripla tablets used for the treatment of HIV-1 infection in adults. It combines three anti-AIDS medicines into a single, daily dose for either first- or second-line treatment and is one of the best-selling AIDS products in

...